Precision Peptide Company Inc

Precision Peptide Company Inc

PNGAF
Precision Peptide Company IncUS flagOther OTC
0.24
USD
+0.04
- -
3.56MMarket Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.13
0.05
- -
- -
- -
Basic EPS, GAAP
- -
-0.25
-0.29
-0.15
-0.21
-0.1
Free Cash Flow per Basic Share
- -
-0.16
-0.17
-0.07
-0.11
-0.08
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
0.27
0.05
-0.02
-0.07
0.02
0.11
Tangible Book Value per Share
0.26
0.05
-0.02
-0.07
0.02
-0.01
Basic Weighted Avg Shares
- -
5
6
7
22
11
Sales/Revenue/Turnover
- -
1
- -
- -
- -
- -
Operating Margin (%)
- -
-154.78
-564.3
-7,545.54
-4,529.94
-89,596.57
Depreciation Expense
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-1
-2
-1
-5
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-194.13
-581.35
-8,450.19
-9,104.28
-98,687.41
Working Capital
1
- -
- -
-1
1
- -
LT Debt
- -
- -
- -
- -
- -
- -
Total Equity
1
- -
- -
-1
1
3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-156.23
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Oct'24
Jan'25
Apr'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
28
Market Capitalization
- -
1
5

Working Capital

FRC

•

in mil. unless spec.
Oct'24
Jan'25
Apr'25
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-268.9%
Free Cash Flow
- -
- -
431.14%
Net Income, GAAP
- -
- -
339.01%
Sales/Revenue/Turnover
- -
- -
307.47%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.03
-0.04
-0.01
- -
-0.15
2025
-0.03
-0.02
- -
- -
-0.21
2026
-0.03
-0.01
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Pratapvir Sandhu
Full Time Employees
2
Sector
Consumer Cyclical
Industry
Restaurants
Address
543 Granville Street Vancouver BC Canada V6C 1X8
IPO Date
Aug 25, 2022
Business
Pangea Natural Foods Inc. (PNGAF) manufactures and distributes plant-based food products and innovative wellness solutions focused on clean-label nutrition and non-injectable peptide therapies in North America. The company offers plant-based patties; old fashioned ghee made from grass-fed organic New Zealand butter; energy gel with apple-based honey for rapid nutrient delivery; vitality, sunshine, and greens blends; plant-based recovery drinks; munchie mix; and co-packing, manufacturing, supply-chain, and distribution services for third-party food and beverage companies; through its subsidiary Amino Innovations Corp., it provides peptide therapies including BPC for rapid muscle and joint recovery, and products targeting stress management, gut health, longevity, hair health, skin repair, sleep health, and immune support via oral and topical delivery systems. Products reach consumers through company websites, over 500 retail outlets across Canada and the United States such as Loblaws, Sobeys, Whole Foods, Save-On-Foods, Choices Markets, and select Air Canada and WestJet flights, as well as wholesale networks. Founded in 2021 and headquartered in Vancouver, British Columbia, Canada, with operations in Surrey, British Columbia, the company serves the packaged foods and consumer wellness sectors targeting health-conscious individuals and growing food brands. In Q2 2025, Pangea completed the acquisition of Amino Innovations Corp. to expand into peptide-based wellness products and needle-less delivery systems; it secured CAD 500,000 in development capital through a private placement in January 2025 and anticipates receiving CAD 2.9 million in additional funding; earlier in 2024, it launched co-packing services for scalability and cost savings while opting not to acquire Glory Juice Co. to prioritize core brand expansion.

Company News

  • The Precision Peptide Company Advances Needle-Free GLP-1 Tirzepatide Patch into Formal U.S. Testing

  • RETRANSMISSION: The Precision Peptide Company Orders 20,000 Thymosin Alpha-1 Patches for Commercial Launch

  • The Precision Peptide Company Orders 20,000 Thymosin Alpha-1 Patches for Commercial Launch

  • The Precision Peptide Company Expands U.S. Wholesale Program, Opening Distribution of Its Needle-Free Range to Clinics, Med Spas, Gyms and Retailers

  • The Precision Peptide Company Becomes Strategic Sponsor of Championing Mental Health 3 Boxing Event

  • The Precision Peptide Company Announces Grants of RSUs and Stock Options

  • The Precision Peptide Company to Showcase Its Needle-Free Recovery Patch and Supplement Range at FitExpo Anaheim

  • The Precision Peptide Company Inc. Announces Development of Needle-Free Tirzepatide Transdermal Patch

  • The Precision Peptide Company Completes Migration of Amino Innovations Online Store and Customer Base to Company Website

  • The Precision Peptide Company Targets Launch of the Peptide Pen, Expanding Its U.S.-Made Product Platform

  • The Precision Peptide Company Opens Nationwide Retail Sales Days After FDA Panel Backs Six of Seven Peptides Under Review

  • The Precision Peptide Company Advances First-to-Market Thymosin Alpha-1 Patch for Immune Support

  • The Precision Peptide Company Applauds FDA Advisory Committee Vote on Expanded Pathway for BPC-157 and KPV

  • The Precision Peptide Company Activates Nationwide Direct-to-Consumer Peptide Sales with Retail Telehealth Website Launch

  • The Precision Peptide Company Inc. Announces Closing of LIFE Offering of Common Shares

  • The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches

  • The Precision Peptide Company Activates Nationwide Direct-to-Consumer Peptide Sales with Retail Telehealth Website Launch

  • The Precision Peptide Company Activates Nationwide Direct-to-Consumer Peptide Sales with Retail Telehealth Website Launch

  • The Precision Peptide Company Appoints Certified Peptide Therapist and Integrative Health Coach Diane Stafrace to Advisory Board

  • The Precision Peptide Company's Needle-Free Recovery Patch Featured in Men's Health Magazine